ShigETEC is Eveliqure's proprietary oral live attenuated vaccine targeting Shigella and enterotoxigenic E. coli (ETEC), two of the major pathogens causing diarrhoeal diseases.
The combination of Eveliqure's innovative vaccine platform with SII’s global development and commercial expertise, together with its leading position in paediatric vaccines, provides a strong foundation for delivering novel vaccines capable of meaningfully reducing the global burden of diarrhoeal diseases.
Read the full press release here